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Abstract
Over a third of brain tumour patients visit their general practitioner more than five times prior to 
diagnosis in the UK, leading to 62% of patients being diagnosed as emergency presentations. 
Unfortunately, symptoms are non-specific to brain tumours, and the majority of these patients 
complain of headaches on multiple occasions before being referred to a neurologist. As there are 
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currently no methods in place for the early detection of brain cancer, the affected patients’ average 
life expectancy is reduced by 20 years. These statistics indicate that the current pathway is ineffective, 
and there is a vast need for a rapid diagnostic test.
Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy is sensitive to the 
hallmarks of cancer, as it analyses the full range of macromolecular classes. The combination of 
serum spectroscopy and advanced data analysis has previously been shown to rapidly and objectively 
distinguish brain tumour severity. Recently, a novel high-throughput ATR accessory has been 
developed, which could be cost-effective to the National Health Service in the UK, and valuable for 
clinical translation.
In this study, 765 blood serum samples have been collected from healthy controls and patients 
diagnosed with various types of brain cancer, contributing to one of the largest spectroscopic studies 
to date. Three robust machine learning techniques - random forest, partial least squares-discriminant 
analysis and support vector machine - have all provided promising results. The novel high-throughput 
technology has been validated by separating brain cancer and non-cancer with balanced accuracies of 
90% which is comparable to the traditional fixed diamond crystal methodology. 
Furthermore, the differentiation of brain tumour type could be useful for neurologists, as some are 
difficult to distinguish through medical imaging alone. For example, the highly aggressive 
glioblastoma multiforme and primary cerebral lymphoma can appear similar on magnetic resonance 
imaging (MRI) scans, thus are often misdiagnosed. Here, we report the ability of infrared 
spectroscopy to distinguish between glioblastoma and lymphoma patients, at a sensitivity and 
specificity of 90.1% and 86.3%, respectively. A reliable serum diagnostic test could avoid the need 
for surgery and speed up time to definitive chemotherapy and radiotherapy.
Introduction
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Brain tumour incidence rates have been increasing since the early 1990s, rising by 34% in the UK 
alone [1]. Despite an improvement in patient survival, only 14% of patients survive 10 years or more 
after diagnosis, and the average reduction in life expectancy of 20 years is the highest of all cancers 
[2]. Rapid and timely diagnosis and determination of tumour type is crucial to expediting 
management and improving patient outcomes [3]. 
The symptoms most frequently associated with brain tumour are non-specific, such as headache, 
presenting a challenge for doctors in identifying which patients with these common symptoms are 
most likely to have a brain tumour, and should have expedited brain imaging [4]. Consequently 
patients often visit their general practitioner (GP) multiple times before diagnosis and for nearly two 
thirds of patients diagnosis is in the emergency department once they deteriorate [5,6]. Existing 
referral guidelines lack sensitivity and specificity, with as few as 1.6% of patients referred for urgent 
brain imaging from primary care having a brain tumour, suggesting many brain scans are unnecessary 
[7]. 
Brain tumours are diagnosed on magnetic resonance imaging (MRI) or computed tomography (CT) 
brain imaging. There are many different types of tumours, depending on the underlying cell of origin, 
each with its own optimal treatment regimens. Crucially, it is not possible to identify the tumour type 
with certainty from imaging alone. For example, primary cerebral lymphoma and glioblastoma 
(GBM) can have similar appearance on MRI [8], but very different therapy options. Patients therefore 
require a gold standard histological tissue diagnosis. This subjects them to surgical tumour biopsy, 
with attendant risks, including stroke or death, and with consequent delay to commencement of the 
chemotherapy and/or radiotherapy that will best impact on their disease. A rapid blood test that can 
identify patients with tumours amongst those with similar symptoms, and that can stratify tumour type 
would have a profound impact. 
Analytical techniques based on vibrational spectroscopy, such as Raman and infrared (IR) 
spectroscopy, have emerged in the field of disease diagnostics [9–12]. Fourier-transform infrared 
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spectroscopy (FTIR) in particular has become increasingly popular in medical research, because of its 
rapid, non-invasive analysis [13]. In FTIR spectroscopy, biological samples are irradiated with 
infrared light. The absorbance of this light causes molecular excitation and enables transitions 
between vibrational states, resulting in an IR spectrum. A typical spectrum of a biological sample 
represents a biochemical fingerprint, and can characterise and quantify the levels of proteins, lipids, 
carbohydrates and nucleic acids that are present. The imbalances in these biomolecular components 
can give an indication of disease states [14]. Machine learning algorithms learn the differences in IR 
biosignatures that are exclusive to disease and can provide a diagnostic output with a prediction on the 
patient’s state [15]. 
Many spectroscopic disease diagnostic pilot studies to date have analysed human tissue, indicating the 
possibility to differentiate healthy and cancerous tissue, as well as benign and malignant tumours [16]. 
Breast, lung, colorectal and prostate lesions have been studied, providing a platform of promising 
results [17–21]. Blood serum contains over 20,000 different proteins and is one of the most complex 
biofluids [22]. Serum perfuses all body organs, gaining proteomes from surrounding tissues and cells, 
making it rich in information, hence the spectroscopic biosignature of serum ideal for indicating 
disease states [23,24].
Attenuated total reflection (ATR)-FTIR spectroscopy is well suited to the analysis of biofluids, as 
only tiny volumes are required and sample preparation is minimal [25,26]. Backhaus et al. 
successfully differentiated breast cancer and healthy controls in a study using blood serum [27]. 
Ollesch et al. introduced automated sampling for the first time, robotically spotting serum for high 
throughput FTIR measurements, in their quest to identify and validate spectroscopic biomarker 
candidates for urinary bladder cancer [28]. Ovarian cancer can be detected from both serum and 
plasma samples, with accuracies of ~95% and ~97% respectively [29]. The serum biosignature for 
cirrhotic patients, with and without hepatocellular carcinoma (HCC), could also be differentiated 
effectively [30]. In brain tumours, Hands et al. were the first to use serum for ATR-FTIR 
spectroscopic analysis. Comparisons have been made between glioma and non-cancer patients [31], as 
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well as different brain tumour types, effectively predicting tumour grade, through spectroscopic 
separation of low grade gliomas from glioblastoma (high grade) [32]. In a further study of blood 
serum from 433 patients [33], a range of primary (glioma, meningioma) and secondary (metastatic) 
lesions were analysed, with sensitivity and specificity values for discrimination of cancer versus non-
cancer of 92.8% and 91.5% respectively [15]. 
Traditional ATR-FTIR instrumentation was used in these studies, which has barred the clinical 
translation of the technique for a number of reasons. Conventionally, an ATR-FTIR spectrometer has 
a fixed point of analysis, known as the internal reflection element (IRE). IREs for ATR analysis are 
made from materials with high refractive indices, the most common being diamond, zinc selenide or 
germanium [34], to contrast with the sample that has a lower refractive index. Biofluid samples are 
deposited directly onto the surface of the IRE before being air dried, in order to combat the spectral 
interference of water [35]. IR light is directed into the IRE and internally reflected, forming an 
evanescent wave at the IRE-sample interface. This evanescent wave interrogates the sample at a 
defined penetration depth, which is dependent upon the refractive indices of the IRE and sample, the 
angle of incidence and the wavelength of IR beam [36]. 
The traditional approach is limited in both cost and time. The IRE materials tend to be high cost, 
therefore would be expensive to replace. The fixed IRE needs to be cleaned between each sample, 
which is extremely time consuming. It takes approximately 8 minutes to adequately dry 1 L of 
human serum on to a diamond crystal, and with the necessary cleaning steps, as well as the technical 
and biological repeats, it would take over an hour to process one patient [32]. Also, scratches on the 
surface of fixed IREs are known to affect the sample-IRE contact, which is essential for ATR-FTIR 
measurements [37]. These limitations have inhibited the progression of the technique thus far, 
however high-throughput ATR-FTIR could overcome these barriers for successful clinical translation. 
A recently published health economic study has suggested a high-throughput alternative to the 
traditional IRE would be cost-effective to the UK’s National Health Service (NHS). Gray et al. 
highlight the clinical and economic benefits of implementing a quick diagnostic test for brain cancers 
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into the current pathway [38]. They reported that a serum blood test at the primary care level could 
prioritise patients for neuroimaging, improving patient survival and quality of life, whilst also saving 
on the cost of unnecessary brain scans. Furthermore, since blood tests at the primary care level are 
already in place, an additional test at this stage would not significantly disrupt current practices. 
Silicon (Si) has a high refractive index, and its relatively low cost - cf. diamond - and transparency to 
infrared light makes it an ideal material for Si IREs (SIREs) [39,40]. High-throughput disposable 
SIREs are now commercially available, that allow single-bounce ATR-FTIR (ClinSpec Diagnostics 
Ltd, UK) [41]. The SIRE replaces the expensive fixed crystal, and allow multiple sampling points. 
The design enables the slides to be batch processed, as well as having the option of repeating analysis 
if required, a feature that would not be possible with conventional fixed SIREs. 
In this study, we further explore the largest retrospective dataset curated to date of serum samples 
from patients with brain tumours, with a specific focus on the spectroscopic interpretation of the 
variances within the brain tumour cohort. Specifically, we elucidate the ability of SIRE-based ATR-
FTIR spectroscopy to successfully identify the cancerous biosignature in serum, and to differentiate 
between glioblastoma and primary cerebral lymphoma. 
Materials and Methods
Sample collection and preparation
Following a specified standard operating procedure, a total of 765 serum samples were obtained from 
three sources; the Walton Centre NHS Trust (Liverpool, UK), Royal Preston Hospital (Preston, UK), 
and the commercial source Tissue Solutions Ltd (Glasgow, UK). Ethical approval for this study was 
obtained (Walton Research Bank and Brain Tumour North West/WRTB 13_01/BTNW Application 
#1108). All experiments were performed in accordance with the University of Strathclyde and NHS 
Lothian ethical guidelines and approved by ethics committees at both institutions, Informed consents 
were obtained from human participants of this study. The primary care triage study contains 724 cases 
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- 487 brain tumour samples and 237 healthy controls. A respectable balance of male and female 
patients has been included, with a widespread age range (Table S1). A large variety of tumour types 
are involved in the brain cancer cohort (Table S2). An additional 41 serum samples were collected 
from patients with primary cerebral lymphoma for comparison against GBM samples (Table S3). 
In order to be included in this study, the cancer patients must have had a pathologically confirmed 
primary or secondary brain tumour, and must not have been undergoing chemo- or radio-therapy at 
the time of collection. For control patients, obtained as above, inclusion criteria stated that they should 
not be undergoing any medical treatments, nor have any history of cancer. Blood samples were 
collected in serum collection tubes and allowed to clot for up to one hour. The tubes were centrifuged 
at 2200 g for 15 minutes at room temperature, then the separated serum component was subsequently 
aliquoted stored in an -80°C freezer. 
Prior to spectral analysis, the frozen serum samples were removed from storage and thawed at room 
temperature (18-25°C) for an average time of 15-20 minutes. Using a micropipette, 3µL of serum 
from one individual patient was deposited onto each of the three sample wells of the optical sample 
slide (wells 1, 2 and 3), whilst ensuring well ‘0’ remained clean for background collection. The serum 
drops were spread across the well using the pipette tip, in order to create a thin serum film and cover 
the whole IRE for more uniform deposition. Prepared slides were stacked in 3D printed polylactic 
acid (PLA) slide holders, which were designed to enable batch drying. The stacked slides were then 
stored in a drying unit incubator (Thermo Fisher™ Heratherm™, GE) at 35°C for 1 hour. Pre-
analytical work prior to beginning this study showed this step to be vital, as it provides even heat and 
airflow for controlled drying dynamics of the serum droplet, to obtain a smooth, flat homogenous 
sampling surface [42–44]. 
Spectral collection
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For this study, a Perkin Elmer Spectrum 2 FTIR spectrometer (Perkin Elmer, UK) was used for the 
spectral collection. A Specac Quest ATR accessory unit was fitted with a specular reflectance puck 
(Specac Ltd, UK), allowing the SIRE to sit on top of the aperture and replace the traditional fixed 
diamond IRE. The Slide Indexing Unit (ClinSpec Diagnostics Ltd, UK) enabled accurate and 
reproducible movement across the specular reflectance puck, indexing the optical slide between 
sample wells. With the first well acting as a background, the three sample wells provide the biological 
repeats. Each well was analysed in triplicate - resulting in nine spectra per patient. The spectra were 
acquired in the range 4000-450cm-1, at a resolution of 4cm-1, with 1cm-1 data spacing and 16 co-added 
scans. In total 6885 spectra have been collected from all serum samples. 
Spectral pre-processing
Here we have used the PRFFECT toolbox within R Statistical Computing Environment software for 
the spectroscopic analysis [45,46], which can be divided into two parts; spectral pre-processing and 
spectral classification. The pre-processing step is commonly applied in spectroscopic studies, as it 
reduces unwanted variance in the dataset. A combination of baseline correction, normalisation and 
data reduction enables the significant biological information be emphasised and improves the 
classification performance [47]. The optimum pre-processing protocol was determined using a trial-
and-error iterative approach. The PRFFECT toolbox offers various pre-processing methods, such as 
binning, smoothing, normalisation and numerical derivatives - we direct the reader towards Smith et 
al. [45] for more information on the use of this open-source program. Figure 1 gives an example of 
the data pre-processing; (a) raw spectra as the mean plot per patient, for the whole 724-patient dataset, 
and (b) shows the spectra cut to the fingerprint region, with baseline correction and a vector 
normalisation applied - greatly reducing the spectral variation. 
Extended multiplicative signal correction (EMSC) has recently been shown to be a reliable pre-
processing tool, that allows more selective correction for various types of scattering [48]. The EMSC 
process scales the IR spectra according to a given reference spectrum. In this case, the reference was 
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an average spectrum of 10 background measurements of the SIRE, which was chosen to minimise the 
spectral variance caused by silicon lattice vibrations. The optimal pre-processing parameters were 
found to be (in order); EMSC, spectral cut to the fingerprint region (1800-1000 cm-1), a minmax 
normalisation and a binning factor of 8.
Spectral analysis
Spectral analysis was carried out to identify the cancerous biosignature from a known patient cohort, 
to develop a trained classification model, and then to use this information to predict the presence of 
cancer in an unknown population. Prior to running the classifications, bootstrapping analysis on the 
training set was carried out to search for an acceptable number of iterations. This technique resamples 
a dataset with replacement, to determine an optimal resample value which will maximise 
classification accuracy [49]. To develop the models, patients were randomly split into training and test 
sets, with a 70:30 split. Models were tuned on the training set (70%) and then used to make 
predictions for the spectra in the test set (30%). Model tuning was carried out by a grid-search of 
model hyper-parameters to maximise Cohen’s Kappa statistic computed on a per-spectra basis for 5-
fold cross-validation on the training set. In order to ensure that the models were trained and validated 
correctly, spectra from a single patient’s sample could only appear in one cross-validation fold, and in 
either the training or test set. The consensus vote amongst the nine spectra that were analysed for each 
patient was reported as the diagnostic outcome (cancer or non-cancer). Model performance is reported 
in terms of sensitivity, specificity, kappa, and balanced accuracy. For those classifications for which 
the class prevalence in the clinical population were known, positive and negative predictive values 
were also computed. 
Sensitivities and specificities (Eq. 1 and 2), are based on the number of correct and incorrect 
predictions in the external test set. The sensitivity refers to the ability of the test to correctly identify 
the patients with the disease (brain cancer), and specificity is the ability to correctly pick out those 
without the disease (controls) [50]. True positives (TP) result from a patient with the target disease 
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with five or more spectra out of their nine spectra correctly identified, whereas true negatives (TN) 
refer to the patients without the target disease who have at least five out of their nine spectra correctly 
identified. False positives (FP) are where a control patient has five or more spectra incorrectly 
identified as cancer, and a false negative (FN) is from a patient with the target disease who has five or 
more spectra incorrectly classified as non-cancer. 
(1)𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 = 𝑇𝑃𝑇𝑃 + 𝐹𝑁 =  𝑇𝑃𝑃
(2)𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁𝑇𝑁 + 𝐹𝑃 =  𝑇𝑁𝑁
where P is the number of real positives and N is the number of real negatives. 
When employing binary classifications on imbalanced datasets, the overall model performance is 
commonly measured using balanced accuracy (Eq. 3), which can be defined as the average accuracy 
obtained on either class [51]. 
) / 2 (3)𝐵𝑎𝑙𝑎𝑛𝑐𝑒𝑑 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = (𝑇𝑃𝑃 + 𝑇𝑁𝑁
In order to understand the reliability of the diagnostic model the Kappa value, , can give a 
quantitative measure of the magnitude of agreement between observers (Eq. 4). 
(4)𝜅 = 𝑝𝜊 ―  𝑝𝑒1 ― 𝑝𝑒
where  is the relative observed agreement and  is hypothetical probability of the chance 𝑝𝜊 𝑝𝑒
agreement, which can be calculated from consideration of the number of times that cancer and non-
cancers occur in the real and predicted data. Values of  range from below zero to one and equate to 
the level of agreement. Where in general,  0 indicates no agreement, 0.01–0.20 accounts for slight, 
0.21–0.40 fair, moderate agreement is 0.41–0.60, 0.61–0.80 is substantial and lastly 0.8–1.00 is 
almost perfect agreement [52,53]. 
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Predictive values are useful to clinicians as they indicate the true likelihood of the test results. The 
positive predictive value (PPV) is the proportion of patients with positive test results who are 
correctly diagnosed, and the negative predictive value (NPV) relates to those with correctly assigned 
negative results [54,55]. The predictive values are dependent upon the sensitivity, specificity and the 
prevalence of the disease (Eq. 5 and 6) - in this case the prevalence of brain tumours [56]. In this 
study the PPV and NPV have been calculated using the mean values of sensitivity and specificity 
from each of the resampled classification models and the prevalence is equal to that of the positive 
class (i.e. cancer) in the clinical environment.
(5)𝑃𝑃𝑉 = 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 ×  𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 ×  𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 +  (1 ― 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦) × (1 ― 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)
(6)𝑁𝑃𝑉 = 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 ×  (1 ― 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)(1 ― 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦) ×  𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 +  𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 ×  (1 ― 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)
To determine the optimum values for the tuning parameters, a 5-fold cross-validation was performed - 
on a patient basis - on the training data. Due to the class imbalance present when examining the 
difference between cancer (487 patients) vs. non-cancer (237 patients), various sampling methods 
were used throughout this study to ensure no bias was present within the models; up-sampling, down-
sampling and synthetic minority over-sampling technique (SMOTE). The up-sampling method 
consists of repeatedly sampling the minority class with replacement to increase the number of 
samples, whereas down-sampling selects a subset of the majority class at random, removing the extra 
samples to make it the same size as the minority class [57]. SMOTE is unique in that it artificially 
mixes the data to, creating ‘new’ samples to achieve a more balanced dataset [58].
Random forest
Random forest (RF) is a robust machine learning technique that for classification problems builds an 
ensemble of decision trees from the training data using the Classification and Regression Trees 
(CART) algorithm [59]. There are three main tuning parameters employed in this technique; ntree is 
the number of trees, mtry is the number of variables available for splitting at each tree node and 
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nodesize refers to the depth of the trees. To encourage diversity amongst the forest, each of ntree trees 
is built on a bootstrap sample of the training data, and at each node in each tree the optimum feature is 
selected from a random subset of mtry available features. Each tree is grown until the terminal nodes 
contain no fewer than nodesize observations. Classification predictions are reported as the majority 
vote of all of the decision trees in the forest, which allows the method to benefit from the “wisdom of 
the crowds”. Random Forest is well-known to be insensitive to the values of ntree, nodesize, and mtry 
[60]. Here, default values were adopted for ntree = 500 and nodesize = 1 and mtry = 30. Additionally, 
spectral importance results can be graphically viewed in the form of Gini plots. The Gini impurity 
metric accounts for how often a randomly selected component from a training set would be 
incorrectly labelled if it was randomly labelled according to the class distribution in a subset [61]. The 
mean decrease in the Gini, also known as Gini importance, is the total decrease in node impurities 
from splitting on the variable, averaged over all trees [62]. This is essentially a measure of how 
important a variable is for estimating the value of the target variable across all tress in the forest. 
Hence, by using this metric, RF can rank the spectral features in order of significance - for example, 
which wavenumbers are the most discriminating between the two classes [15]. 
Partial least squares-discriminant analysis
Partial Least Squares – Discriminant Analysis (PLS-DA) is supervised machine learning method that 
combines PLS regression (PLSR) and Linear Discriminant Analysis (LDA). This technique can 
extract important information from complex datasets, by reducing the dimensionality to reveal hidden 
patterns within the data. For binary classification problems, the technique separates classes by looking 
for a straight line that divides the data space into two distinct regions [63]. The data points are 
projected perpendicularly to the line, which is known as the discriminator [64]. The distances from 
the discriminator are referred to as the discriminant scores [65]. This information is provided in the 
form of new variables called PLS components, where the first PLS component (PLS1) accounts for 
the greatest variation in the dataset, PLS2 represents the next greater variation, and so on. PLS scores 
plots give an overview of the general inconsistences within large datasets, and loadings plots further 
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explain the variance, by suggesting where the most variable regions exist e.g. which spectral regions 
display the highest disparity. The optimal number of components, ncomp, is determined when tuning 
the classification models. The best value for ncomp provides the most reliable results, so that the 
cross-validation error is minimized. 
Support vector machine 
A support vector machine (SVM) is a supervised algorithm, commonly employed for classification 
purposes [66]. From known data, SVM outputs an optimal dimension for the separation of the data, 
known as the hyperplane. Support vectors are the co-ordinates of the individual observation and the 
hyperplane can be used to categorise new samples [67]. Linear, radial basis function, and polynomial 
kernels have all been used in SVM models. Here we use the linear kernel that has previously been 
shown to perform well in spectral classification studies [68]. The optimization of SVM tuning 
parameters can change the classification efficiency dramatically. The penalty parameter cost is 
responsible for the trade-off between smooth boundaries and the ability to classify the data [69]. 
Results
Brain Cancer vs Control
Each classification model was executed multiple times to ensure the variance within the dataset was 
fully encompassed. Bootstrapping analysis on the training set showed 51 resamples to be a reliable 
number of iterations, as shown in Figure 2, the standard error adequately converges at around 51 
resamples for both (a) sensitivity and (b) specificity. A higher number of iterations reduces the 
variance, but also increases the time required to run the classification models. At 51 iterations, the 
standard error for the test set was 0.13% for sensitivity and 0.19% for specificity, which was deemed 
to be an acceptable level of error, with reasonable analysis time.
Random forest results
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Following optimal pre-processing, a single RF classification model was trained on the training data 
and used to predict the test set. The value of mtry was chosen to be 30, which gave sensitivity and 
specificity of 93.8% and 80.1% for the 5-fold cross-validation on the training data. Initial analysis of 
the single RF model emphasised the ability to successfully pick out the brain cancer patients from the 
training set, with the test set reporting a sensitivity of 92.5%. However, the specificity was much 
lower at 76.1%, meaning this particular model incorrectly predicted many of the control patients as 
having the disease. That said, the lower specificity could be attributed to the class imbalance within 
the dataset. As the sensitivity of a model relates to the ability to detect patients with disease, and 487 
out of the 724 patient samples were cancerous, there was a bias towards the prediction of a brain 
cancer. The addition of statistical sampling techniques can reduce the class imbalance and improve 
the accuracy of the model. Table 1 compares classification output of the initial RF model with the 
three different resampling techniques. The up-sampling method was not effective in improving this 
model, losing 0.7% on sensitivity and only increasing specificity by 1.4%. On the other hand, down-
sampling greatly improved the specificity, rising from 76.1% to 85.9%. Some studies have been 
critical of down-sampling, as the technique ‘ignores’ data that could provide important differences 
and/or similarities between the two classes [70] That being said, multiple iterations could potentially 
overcome this data loss, as there would be different samples down-sampled during each iteration. 
With SMOTE sampling technique, the minority class (controls in this case) is synthetically up-
sampled in order to be more comparable with the majority class [58]. This was found to provide the 
best output, with a sensitivity and specificity of 94.5% and 88.7% respectively. 
Table 1 - Sampling comparison for single random forest classifications
RF only Up-sampling Down-Sampling SMOTE
Sensitivity (%) 92.5 91.8 90.4 94.5
Specificity (%) 76.1 77.5 85.9 88.7
Figure S1 shows the confusion matrices of the (a) initial and (b) SMOTE models which describe the 
predictions that were made in the random forest test sets. As outlined above in Table 1, the specificity 
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increased to 88.7%, predicting 63 out of 70 non-cancer patients correctly. The sensitivity remained 
high, only falsely predicting 8 out of 146 cancer patients as non-cancer, resulting in a sensitivity of 
94.5%. As the SMOTE sampling was found to be optimal in this case, it was used for the resampled 
classification. 
The single model results were promising, but to ensure they were reliable, the RF model was 
resampled 51 times. The 51 independent RF models were combined to provide mean sensitivity and 
specificity values, as well as the standard deviations to account for the statistical variance. Table 2 
lists the mean and standard deviation (SD) values for the sensitivity, specificity,  and balanced 
accuracy relating to the 51 RF iterations. The PPV and NPV were also calculated from the mean 
sensitivity and specificity, as well as the prevalence of brain tumours - reported as approximately 
1.6% [7]. The ability to successfully predict the brain cancer patients was high, with an average 
sensitivity of 93.1%. However, despite SMOTE being more beneficial for the singular RF model, the 
average specificity over the 51 iterations dropped to 81.1%, ranging from 73.2% to 92.9%. This 
particular RF classification performed well in the detection of brain cancer within this dataset, but it 
was incorrectly assigning more of the non-cancer patients as ‘cancer’, resulting in a higher number of 
false positives. Clearly this would not be very efficient for the clinic, as the excess brain scans would 
be costly to the health services, meanwhile putting healthy patients through needless stress and 
anxiety. However, these findings are still relatively promising, with a health economic study reporting 
statistics >80% would be cost-effective to the NHS [38]. 
Table 2 - Statistical results for the test set in the RF model with 51 iterations
Mean SD
Kappa Value 0.75 0.05
Sensitivity (%) 93.1 1.97
Specificity (%) 81.1 3.90
Balanced Accuracy (%) 87.1 2.35
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PPV (%) 7.4 -
NPV (%) 99.9 -
The Gini impurity metric was examined to identify the most important features within the dataset. The 
accuracy and reliability of the model can be determined from the RF statistical value outputs, with the 
Gini plot highlighting wavenumbers responsible for the results for the optimal model (Figure 3). 
Table 3 gives an overview of the top 15 identified wavenumbers in order of importance, with their 
corresponding wavenumber assignments and vibrational modes. The column "∑Gini" in the table is a 
summation of the mean decrease in Gini for each wavenumber, over all nodes in all trees in the 
ensemble. 
Table 3 - Top 15 wavenumbers from RF classification of brain cancer vs non-cancer with 
tentative biochemical assignments [14,16]
Wavenumbers (cm-1) ∑Gini Tentative Assignments Vibrational Modes
1524.5 619.1
1516.5 430.0
1532.5 425.7
1508.5 193.2
Amide II of proteins (N-H), ν(C-N), (C-O), ν(C-C)
1028.5 177.8
1036.5 150.0
Glycogen ν(C-O), ν(C-C), def(C-OH)
1500.5 120.7
1540.5 95.2
Amide II of proteins (N-H), ν(C-N), (C-O), ν(C-C)
1020.5 90.9 DNA/Glycogen  ν(PO2-)/ν(C-O)
1788.5 83.2 Lipids ν(C=O)
1044.5 79.3 Nucleic Acids ν(PO2-)
1796.5 79.1 Lipids ν(C=O)
1668.5 76.1 Amide I of proteins ν(C=O), ν(C-N), (N-H)
1012.5 67.2 Carbohydrate ν(C-O)
1492.5 67.1 Amide II of proteins (N-H), ν(C-N), (C-O), ν(C-C)
ν = stretching;  = bending; def = deformation
The most discriminatory region is the Amide II band, making up the top 4 wavenumbers with 
extremely high ∑Gini values. The out-of-phase combination of the NH bending and the CN stretching 
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vibrations, as well as minor contributions from the CO in-plane bend and the CC/NC stretching 
vibrations, give rise to the Amide II band [71]. Certain wavenumbers in the lower wavenumber region 
- relating to carbohydrates, glycogen and nucleic acids – were also shown to be highly discriminating. 
These areas of importance are closely followed by lipid and other protein (Amide I) contributions. 
PLS-DA results
The optimal value of ncomp was found to be 14, which was selected from a tuning grid with a range 
1:20. This gave sensitivity of 89.4% and specificity of 88.7% for the 5-fold cross-validation on the 
training data. An initial PLS-DA model reported a sensitivity of 95.9% and specificity of 81.7% for 
the external test set. Similar to the RF analysis, the sampling techniques were used to balance the 
classes. All three methods greatly enhanced the specificity, each improving by 10% or greater (Table 
4), but this was costly for the sensitivity values, each falling below 90%. It is likely that the fall in 
sensitivity is caused by the class imbalance, as the initial model can be biased and overpredict the 
majority of the patients as ‘cancer’, simply because there is many more within the dataset. The 
sampling techniques balance the classes, giving an impartial representation and hence more reliable 
predictions. Again, as with the RF, the best results were obtained using SMOTE sampling (Figure 
S2), hence 51 iterations of the RF + SMOTE classification was employed. 
Table 4 - Sampling comparison for single PLS-DA classifications
PLS-DA only Up-sampling Down-Sampling SMOTE
Sensitivity (%) 95.9 86.3 86.3 89.7
Specificity (%) 81.7 92.9 94.3 91.6
Table 5 lists the results from the 51 resamples of the PLS-DA/SMOTE model. PLS-DA was not as 
effective at predicting the brain cancer patients correctly, reporting an average sensitivity of 90.5%, in 
comparison to 93.1% for the RF model. However, the average specificity was 91.1%, meaning PLS-
DA was far superior in correctly assigning the control samples as ‘non-cancer’. Out of the three 
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classification models, PLS-DA reported the best PPV, at 14.2%, almost double that of the RF model 
(7.4%).
Table 5 - Statistical results for the test set in the PLS-DA + SMOTE model with 51 iterations
Mean SD
Kappa Value 0.71 0.10
Sensitivity (%) 90.5 2.09
Specificity (%) 91.1 3.28
Balanced Accuracy (%) 90.8 1.83
PPV (%) 14.2 -
NPV (%) 99.8 -
Figure 4 shows the scores plot between the first and second PLS components. There is a substantial 
amount of overlap between the two classes, with some separation across the 2nd PLS component 
(PLS2). The loadings plot for PLS2 is described in Figure 5, which suggests the biggest variance 
within the brain tumour dataset exists in the Amide II region (1500-1600cm-1), and in the lower 
wavenumber region (1000-1100cm-1). This agrees with the RF Gini importance values, in that the 
Amide II of proteins, and the bands from glycogen/carbohydrate/phosphate vibrations are most 
discriminatory.
SVM results
Similar analysis was carried out using an SVM-based classification (Table 6). The SVM model was 
tuned using the optimal value for cost, which was determined to be 0.019 by running a sequence 
between 0.001 and 0.03 at intervals of 0.018. Again, the use of the sample balancing techniques 
greatly improved the accuracy of the model, with SMOTE being the preferred method. The linear-
SVM with SMOTE single model performed slightly better than RF and PLS-DA, with both sensitivity 
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and specificity above 90%, as described in the test set confusion matrices (Figure S3). Table 7 reports 
the statistics for the 51 SVM iterations using SMOTE. 
Table 6 - Sampling comparison for single SVM classifications
SVM only Up-sampling Down-Sampling SMOTE
Sensitivity (%) 93.2 89.7 87.7 91.7
Specificity (%) 81.7 94.4 94.4 90.1
Table 7 - Statistical results for the test set in the SVM model with 51 iterations
Mean SD
Kappa 0.80 0.03
Sensitivity (%) 92.1 2.1
Specificity (%) 88.7 3.3
Balanced Accuracy (%) 90.4 1.5
PPV (%) 13.5 -
NPV (%) 99.9 -
Here, the average sensitivity was 92.1% but the specificity was slightly lower at 88.7%. Again, we 
achieve a balanced accuracy over 90%, and the PPV of 13.5% is relatively high. The SVM model 
produced a mean  value of 0.8, indicating almost perfect agreement which suggests this particular 
model was robust and reliable. 
ROC curves
In addition, receiver operating characteristic (ROC) curves can illustrate the diagnostic ability of 
machine learning classifiers, and aid with tuning the classification model for clinical applications. The 
area under the curve (AUC) represents the measure of separability, with the higher AUC the better the 
model is at distinguishing between classes [72]. The ROC graph in Figure 6 suggests the diagnostic 
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performance of all three models is extremely promising. The ROC curves are all relatively 
symmetrical across sensitivity and specificity - the PLS-DA curve is slightly better with an AUC 
value of 0.948, which is regarded as excellent. 
In general, the results from this study confirm the ability of serum spectroscopy - coupled with 
computational analysis - to be effective in differentiating brain lesions from healthy controls. Using 
basic machine learning techniques, we have successfully separated brain cancer and non-cancer with 
accuracies greater than 90%. Both PLS-DA and SVM performed extremely well, with the PLS-DA 
model reporting an average sensitivity and specificity of 90.5% and 91.1% respectively, meanwhile 
the linear-SVM produced 92.1% sensitivity and 88.7% specificity. These results are just slightly 
inferior to the 92.8% and 91.5% reported by Hands et al. [33]. However, there are various differences 
between these studies, meaning they are not entirely comparable. The patient cohorts were comprised 
of different patients, and this dataset contains almost 300 more serum samples. Hands et al. employed 
a radial basis function (RBF) based SVM, whereas we compare the capability of linear-SVM to basic 
RF and PLS-DA models, all of which provided promising results. Despite these differences, 
accuracies above 90% suggests that the new SIRE technology is comparable with the traditional fixed 
diamond IRE, indicating the high-throughput design could now be implemented into the clinical 
environment, to enable a quick blood test for the early detection of brain cancer.
Glioblastoma Multiforme vs Lymphoma
Neuro-oncologists are particularly interested in the challenge of differentiating of primary cerebral 
lymphoma from GBM. It can often be difficult to distinguish between these diagnoses on brain 
imaging alone, such as magnetic resonance imaging (MRI). This therefore necessitates patients to 
have surgical biopsy in order to identify the tumour pathology, and to determine the most appropriate 
regimen of surgery, chemotherapy and radiotherapy. A reliable serum diagnostic test could avoid the 
need for surgery and speed up time to definitive chemotherapy and radiotherapy. 
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Additional serum samples were collected from the Walton Centre and the Royal Preston hospital, to 
provide a total of 41 lymphoma samples. A random subset of the GBM samples from the 724 patient 
dataset were used for the comparisons. The patient information is summarised in supplementary 
information Table S3.
Similar to the 724 dataset, bootstrapping analysis was done on the lymphoma vs GBM training set to 
search for an acceptable number of iterations; 51 resamples were also found to be sufficient, with the 
standard error converging at this point (Figure S4). An initial RF model provides us with the 
biochemical differences between the lymphoma and GBM patients. The Gini plot (Figure 7) suggests 
the Amide II region is of particular importance, closely followed by the Amide I band. Between 1150-
1000cm-1 there are various significant bands, relating to vibrations within nucleic material, glycogen 
and carbohydrates (Table 8). 
Table 8 - Top 15 wavenumbers from RF classification of lymphoma vs GBM with tentative 
biochemical assignments [14,16]
Wavenumbers (cm-1) ∑Gini Tentative Assignments Vibrational Modes
1556.5 95.9
1564.5 91.4
Amide II of proteins (N-H), ν(C-N), (C-O), ν(C-C)
1676.5 57.9
1684.5 50.1
Amide I of proteins ν(C=O), ν(C-N), (N-H)
1572.5 42.9
1548.5 32.6
Amide II of proteins (N-H), ν(C-N), (C-O), ν(C-C)
1668.5 32.2
1660.5 30.5
Amide I of proteins ν(C=O), ν(C-N), (N-H)
1020.5 19.7 DNA/Glycogen  ν(PO2-)/ν(C-O), def(C-OH)
1100.5 19.0 Nucleic Acids  ν(PO2-)
1036.5 17.4 Glycogen ν(C-O), ν(C-C) 
1692.5 15.3 Amide I of proteins ν(C=O), ν(C-N), (N-H)
1108.5 14.6 Carbohydrate ν(C-O), ν(C-C)
1628.5 14.5
1620.5 13.2
Amide I of proteins ν(C=O), ν(C-N), (N-H)
ν = stretching;  = bending; def = deformation
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For the PLS-DA model, in this case the optimal value for ncomp was found to be 4. As with the C/NC 
set, the scores plot separates the lymphoma and GBM patients across the 2nd PLS component (Figure 
8). Again, we see the highest discrimination arises from the Amide bands and the lower wavenumber 
region on the loadings plot (Figure 9). For lymphoma vs GBM, the Amide I region is also highly 
discriminatory, substantiating the RF Gini findings outlined previously in Table 8. The confusion 
matrix for a single PLS-DA model is described in Figure S5. SMOTE showed to be the best sampling 
technique for RF and PLS-DA, but up-sampling was found to be optimal for the SVM-based model 
(Table 9). The PPV and NPV are not included here, as the prevalence value for this particular 
classification is difficult to estimate.
Table 9 - Statistical results for the lymphoma vs GBM test sets from the three different 
classification models with 51 iterations
RF + SMOTE PLS-DA + SMOTE SVM + UP
Mean SD Mean SD Mean SD
Kappa 0.63 0.13 0.76 0.09 0.72 0.11
Sensitivity (%) 90.9 5.8 90.1 5.7 86.6 8.5
Specificity (%) 70.8 14.9 86.3 9.4 86.3 9.5
Balanced Accuracy (%) 80.8 7.2 88.2 5.0 86.4 5.4
For this particular dataset, the sensitivities refer to the ability to detect GBM, and the specificity 
relates to lymphoma. As shown in Table 9, the inferior model for this dataset was found to be RF – 
despite having a high sensitivity, the specificity was rather low at 70.8%. Although the balance 
between sensitivity and specificity could be tuned by optimising the probability threshold of the 
classifier, the fact that Kappa and balanced accuracy have significantly lower values than for the other 
models suggests that it would not change the rankings of the models. SVM combined with up-
sampling performed well, reporting a balanced accuracy of 86.4%. The PLS-DA + SMOTE method 
seemed to be the optimal model, with a sensitivity of 90.1%, a specificity of 86.3%, and the highest  
value of all three models – mean  = 0.76. The sensitivities were relatively stable, but the predictions 
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for lymphoma were more variable, for example, one of the RF resamples reported a sensitivity of 
42%, which ultimately lowered the mean value. That said, the ROC curves for both the SVM-based 
and PLS-DA models still indicate promising diagnostic capability, with AUC values of ~0.9 (Figure 
10). The RF ROC curve is substantially lower across sensitivity and specificity compared to the other 
two techniques, reporting a much lesser AUC value of 0.829, which coincides with the lower 
balanced accuracy from the RF classification. For this diagnostic test to be validated, it could be said 
that more patients would have to be introduced. However, these results indicate the potential for a 
serum diagnostic tool at the secondary care stage, that could aid clinicians when brain scans are 
inconclusive. Furthermore, it would be beneficial if this type of blood test could prevent patients 
undergoing unnecessary surgical biopsy. 
Conclusion
The implementation of a quick blood serum test for the early detection of brain tumours at a GP 
setting could have a huge impact on the quality of life and prognosis for patients. The traditional fixed 
diamond crystal limited the translation of the technique, as the methodology was laborious, requiring 
long drying times and cleaning of the crystal between measurements [33]. An earlier health economic 
assessment in advance of prospective clinical data, stated the development of a high-throughput ATR 
accessory would be cost-effective to the UK’s NHS if sensitivities and specificities >80% were 
achieved [38]. This study validates the capability of the novel ClinSpec Dx SIRE optical sample 
slides [41].
We report a sensitivity and specificity of 90.5% and 91.1% respectively when separating brain cancer 
patients from healthy controls, through PLS-DA. Despite the prevalence of brain tumours being 
extremely low (1.6%), the PLS-DA model reported a PPV of 14.2%. Three different machine learning 
techniques have been compared, all of which report balanced accuracies of ~90%, which would be 
deemed sufficient to be cost-effective to the NHS. Analysis of blood serum using this novel technique 
would fit ideally in the clinical pathway as a primary care triage tool for brain cancer. For the 
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effective treatment of this disease, it is vital to identify the tumours early. A test at this stage in the 
diagnostic pathway would provide GPs with further information to inform their referral decision. If 
test a positive result for cancer was reported from a spectroscopic triage test, then the ‘at risk’ patients 
would progress into secondary care quicker, whilst a negative result would provide reassurance. The 
time taken to diagnose brain cancer patients could be reduced significantly, whilst also saving on 
NHS funds. 
By training a classification algorithm on this known population, new patient samples can be predicted 
based upon the derivation of cancer signals from the retrospective dataset, providing an appropriate 
measure of the true diagnostic accuracy. The first prospective clinical study employing ATR-FTIR 
spectroscopy is presented in Butler et al. [41] which is the first initial analysis of an ongoing clinical 
study at the Western General Hospital, in Edinburgh.
Additionally, we present the ability of this technique to differentiate between brain tumour types. 
Notably, the separation of lymphoma and GBM through ATR-FTIR spectroscopy would be 
particularly attractive for neurologists in a secondary care setting, when imaging results are not clear. 
This proof-of-principle study involved 112 patients, providing a sensitivity of 90.1% and a specificity 
of 86.3%. These statistics are hugely promising, and a  value of 0.76 indicates the technique is 
reliable. Further analysis with a larger cohort of patients would be valuable, in order to make the 
diagnostic model more robust. 
Analysis of the ROC curves and consideration of the prevalence of the diseases to be diagnosed 
suggests that in some cases the models presented here could be optimised for clinical applications by 
modifying the probability threshold that each classifier uses to discriminate between positive and 
negative classes. For example, to identify brain tumours, which have low prevalence of ~1.6% in the 
clinical population, the balance between sensitivity and specificity is important, since the probability 
that a positive test result is truly indicative of a brain tumour (i.e. PPV) increases rapidly with 
specificity. Nonetheless, we believe this kind of optimisation can be done more accurately once more 
Page 24 of 36Analyst
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A
na
ly
st
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
07
 O
ct
ob
er
 2
01
9.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f E
di
nb
ur
gh
 o
n 
10
/7
/2
01
9 
9:
43
:1
4 
PM
. 
View Article Online
DOI: 10.1039/C9AN01731C
is understood about the clinical population, which for the lymphoma vs GBM test in particular is not 
yet fully known. Therefore, the classifiers presented here all correspond to a default probability 
threshold of 0.5 used to discriminate between positive and negative classes, which is sufficient to 
demonstrate their efficacy.
The potential for high-throughput spectroscopy in the clinical environment goes further than purely 
brain tumour detection. With more research, this platform technology could address the clinical need 
for various malignancies and other diseases. There are also gaps for this technology in secondary care 
scenarios, for patient disease progression, treatment monitoring, and potentially aiding oncologists 
when MRI scans are inconclusive, as discussed in this study. The ultimate goal is to make the 
diagnostic pathways more efficient, cost effective and allow patients to obtain early treatment for 
optimal outcome.
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Figures
Figure 1 - Pre-processing example; (a) raw infrared data, and (b) pre-processed
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Figure 2 - Bootstrapping analysis to determine sufficient number of resamples required for the 724 
patient dataset: (a) the sensitivity and (b) specificity
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Figure 3 - Gini importance plot from random forest analysis showing the mean spectra from brain 
cancer (black) and control (red). Blue: Protein; Yellow: Lipid; Green: Nucleic acid and Orange: 
Carbohydrate
Figure 4 - Partial least squares-discriminant analysis; scores plot for brain cancer (black) vs control 
(red) 
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Figure 5 - Loadings plot for the 2nd partial least squares component with tentative biological 
assignments
Figure 6 – ROC curves displaying trade-off between sensitivity and specificity of the three 
classification techniques for the cancer vs non-cancer patients: random forest; Green, partial least 
squares-discriminant analysis; Blue, support vector machine; Red
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Figure 7 - Gini importance plot from random forest analysis showing the mean spectra from 
lymphoma (black) and glioblastoma (red). Blue: Protein; Yellow: Lipid; Green: Nucleic acid and 
Orange: Carbohydrate
Figure 8 – Partial least squares-discriminant analysis; scores plot for lymphoma (black) vs 
glioblastoma (red)
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Figure 9 - Loadings plot for the 2nd PLS component in the lymphoma vs glioblastoma classification 
with tentative biological assignments
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Figure 10 – ROC curve displaying trade-off between sensitivity and specificity of the three 
classification techniques for the lymphoma vs glioblastoma patients: random forest; Green, partial 
least squares-discriminant analysis; Blue, support vector machine; Red
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